Acutaas Chemicals Ltd Q2 FY26 — “When a Specialty-Chem Lab Turns Into a Battery-Chemical Superstar With a P/E Higher Than Its Solvent Purity”
1. At a Glance
Acutaas Chemicals Ltd (NSE: ACUTAAS) — the artist formerly known as Ami Organics — has become the new obsession of Dalal Street’s caffeine-fueled chemical bulls. The stock trades around ₹ 1,647, up 107 % YoY, giving it a market cap of ₹ 13,483 cr and a P/E of 60 × — because apparently “high purity intermediates” also means “high valuation tolerance.”
Q2 FY26 results were lab-tested and investor-approved: Revenue ₹ 306 cr (+24 % YoY), EBITDA ₹ 95 cr (31 % margin), PAT ₹ 72 cr (+94 % YoY). ROE = 16 %, ROCE = 20 %. Debt? Just ₹ 12.9 cr — practically pocket change in a world where some pharma peers owe more than small nations.
So what happens when a once-humble pharma-intermediate maker adds “battery chemicals” and “semiconductors” to its LinkedIn bio? You get a microcap with a superhero complex — and investors who don’t mind paying 10 × book value to feel the buzz.
2. Introduction
Picture this: a small Surat-based R&D company that once synthesized molecules for Lupin and Sun Pharma suddenly starts talking about electrolytes, lithium, and South Korea. That’s Acutaas Chemicals for you — India’s latest case of “From Tablets to Tesla.”
The firm began life as a boutique pharma-intermediate shop, serving big names quietly. Then came the IPO, the name change, the sustainability medals, and now the transformation into a global “specialty + battery + semiconductor” cocktail. All that with four plants, 15 patents, 130 scientists, and zero chill.
While traditional chemical peers fight raw-material inflation, Acutaas is signing MoUs worth ₹ 530 cr with the Gujarat government and South Korean partners. And thanks to its EcoVadis Gold Medal, the firm now sits in the world’s top 5 % for sustainability — a fancy way of saying “we finally learned waste management.”
But is this high-purity story pure performance or just high PE fumes? Grab your goggles; let’s inspect the lab.
3. Business Model – WTF Do They Even Do?
Think of Acutaas as a three-headed chemist:
Pharma Intermediates (85 % of revenue) – Over 550 molecules across 17 therapeutic areas. They supply everything from antidepressant precursors to anti-cancer NCE building blocks. Top clients: Sun Pharma, Cipla, Zydus, Lupin, Midas Pharma. When these giants launch new drugs, Acutaas gets the chemical invite to the party.
Specialty Chemicals (15 %) – 60 + products used in cosmetics, agro, fine chemicals, and electronics. From parabens and methyl salicylate to semiconductor precursors and electrolyte additives. Basically anything that can either power a battery or burn a hole in your lab coat.
CDMO & Battery Chemicals (Emerging) – Where the real future lies. A multi-block Ankleshwar facility is being custom-built for contract manufacturing patented molecules and electrolyte solutions for EV cells.
Geography? Export heavyweight — 74 % revenue from abroad, spanning 55 countries. It’s the kind of Indian company that sends more shipments to Europe than emails to its own HR.
4. Financials Overview
Source table
Metric (₹ Cr)
Q2 FY26
Q2 FY25
Q1 FY26
YoY %
QoQ %
Revenue
306
247
207
+24.1
+47.8
EBITDA
95
49
51
+93.9
+86.2
PAT
72
38
44
+89.5
+63.6
EPS (₹)
8.82
4.56
5.41
+93.5
+63
Commentary: Those margins aren’t just healthy — they’re training for Olympic weightlifting. Operating margin of 31 % and PAT margin near 24 % make most pharma companies look like discount shops. Annualised EPS ≈ ₹ 35 → forward P/E ~47×. Expensive? Yes. Deserved? Investors say “lab tested and approved.”
5. Valuation Discussion – Fair Value Range Only
a) P/E method
FY26E EPS ₹ 35 – 38
Assign sector multiple 40 – 50× (high-growth chemicals) → Fair Value ₹ 1,400 – ₹ 1,900 per share
